Before the results of the 1st CRL, MSB reached a valuation of AU$3.2B. We're currently sitting at a market cap of AU$1.06 (@$0.91 SP). The stock market is full of wild valuations because retail investors typically don't know how to value companies fairly.
I consider that MSB is in a better position than they were back then in their other pipeline times because:
- AA for HLHS on the horizon next year
- Voucher for HLHS
- AA for CHF+LVAD
- CLBP delivering impressive pain relief and opiate reduction in backpain + 2nd trial started
The main negative difference is that CHF did not get the results for full approval from the one trial and the covid hype for ARDS has died down.
Because we are in a similar if not better position, logic should suggest a re-rate to at least the levels MSB was at before the 1st CRL.
This would give an SP of AU$2.75 upon first approval.
Net cash usage in FY 2024 was US$48.5m.
If Ryoncil is reimbursed at:
- US$300k (low estimate), then MSB needs to treat just 162 patients to earn US$48.5m in revenue.
- US$500k (medium estimate), then MSB needs to treat just 97 patients to earn US$48.5m in revenue.
- US$700k (high estimate), then MSB needs to treat just 70 patients to earn US$48.5m in revenue
Those revenue figures represent break even with the current cash burn rate. With the Early Access Program (EAP) in place for many years, the clinicians currently utilizing it will become immediate payors upon approval, before any sales and marketing.
Additionally, AA of HLHS offers the promise of a Priority Review Voucher (PRV) with estimated value of US$100m.
"The reported purchase prices of PRVs to third parties averages about $100 million (range $67.5 million to $350 million) [21, 22]."
Once MSB is able to self-sustain its commercialisation, then its valuation should go bonkers considering its pipeline and results to date in blockbuster indications.
As I've said, if you look at acquisitions in pharma recently:
Acquired Acquirer Development Stage Disease Value 1 Morphic Holdings Eli Lilly During Phase II Crohn's AU$4.8B 2 Cerevel Therapeutics AbbVie During Phase III Parkinsons/Neuro AU$13.1B 3 Nerio Therapeutics Boehringer Ingelheim Preclinical Oncology AU$2B 4 Carmot Therapeutics Roche During Phase II Cardiovascular AU$4.1B 5 Karuna Therapeutics Bristol Myers Squibb During Phase III Schizophrenia AU$21B 6 Cardior Pharmaceuticals Novo Nordisk During Phase II Cardiac AU$1.7B
Then I suspect a mature biotech that is fiscally self-sufficient with Phase III candidates in CHF, HLHS, CLBP, GvHD, ARDS and a Phase II asset in Crohn's - would be valued very favourably... back of envelope valuation of current assets below:
Asset Stage Disease Hypothetical Value Ryoncil Filing GvHD (Oncology) AU$5B Ryoncil Phase II Crohn's AU$5B Ryoncil Phase III ARDS AU$10B Revascor Filing through AA (?) HLHS AU$5B Revascor Filing through AA CHF AU$20B Revascor Phase III CLBP AU$10B Total AU$55B Price Per Share AU$47.74
I'm not saying those are accurate valuations, but I am saying that considering recent acquisitions in the space, they're roughly in the right ballpark.
Reminding ourselves that a valuation of just AU$20B is worth $17.36 per share, and AU$10B is $8.68 per share, I think the upside is pretty darn good providing MSB finally gets the approval.
Not investment advice.
Cheers,
Gang Gang
- Forums
- ASX - By Stock
- MSB
- Entering the PAZ - give us your predictions!
Entering the PAZ - give us your predictions!, page-94
-
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
93.5¢ |
Change
0.020(2.19%) |
Mkt cap ! $1.067B |
Open | High | Low | Value | Volume |
92.0¢ | 94.5¢ | 92.0¢ | $1.622M | 1.742M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 64563 | 93.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
94.0¢ | 204239 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 64563 | 0.930 |
6 | 79973 | 0.925 |
13 | 254982 | 0.920 |
11 | 107275 | 0.915 |
4 | 115328 | 0.910 |
Price($) | Vol. | No. |
---|---|---|
0.940 | 204239 | 3 |
0.945 | 22942 | 2 |
0.950 | 91123 | 5 |
0.955 | 42425 | 1 |
0.960 | 61820 | 3 |
Last trade - 16.10pm 11/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |